趋化因子及其受体是肿瘤细胞生物学行为的重要调节因素。
Chemokines and chemokine receptors are important regulatory factors in tumor behaviors.
在炎症性肠病中，许多趋化因子及其受体表达增加，并在发病机制上起着重要作用。
Many chemokines and their receptors show increased expression in inflammatory bowel disease, which play an important role in the pathogenesis of the disease.
针对趋化因子及其受体的靶向治疗能减轻炎症损伤，可望成为一种新的炎症性肠病的治疗方法。
Targeted therapy that aims directly at chemokines and their receptors can ameliorate inflammatory damage, and can be a novel therapeutics for inflammatory bowel disease.
目的：探讨趋化因子受体CCR7在不同类型肺癌组织中的表达及其临床意义。
AIM: to investigate the expression of CC chemokine receptor 7 (CCR7) in different types of lung carcinoma and its clinical significance.
全文就新近发现的趋化因子受体CCR7及其配体CCL21和CCL19的研究进展作一综述。
The aim of this article is to review recent development of CCR7, a newly identified chemokine receptor, and its ligand CCL21and CCL19.
全文就新近发现的趋化因子受体CCR7及其配体CCL21和CCL19的研究进展作一综述。
The aim of this article is to review recent development of CCR7, a newly identified chemokine receptor, and its ligand CCL21and CCL19.
应用推荐